480 related articles for article (PubMed ID: 37833948)
1. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
Fedele E
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
[TBL] [Abstract][Full Text] [Related]
2. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
[TBL] [Abstract][Full Text] [Related]
3. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
4. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
Lu D; Dou F; Gao J
Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
[TBL] [Abstract][Full Text] [Related]
6. Passive Immunotherapies Targeting Amyloid-
Marković M; Milošević J; Wang W; Cao Y
Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
[TBL] [Abstract][Full Text] [Related]
7. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
10. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
11. Critical Appraisal of Amyloid Lowering Agents in AD.
Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
[TBL] [Abstract][Full Text] [Related]
12. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
13. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
14. Updates on pharmacological treatment for Alzheimer's disease.
Tipton PW
Neurol Neurochir Pol; 2024; 58(2):150-160. PubMed ID: 37606550
[TBL] [Abstract][Full Text] [Related]
15. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
16. Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies.
Vijayan D; Chandra R
Curr Drug Targets; 2020; 21(2):148-166. PubMed ID: 31385768
[TBL] [Abstract][Full Text] [Related]
17. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
[TBL] [Abstract][Full Text] [Related]
18. The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
Tolar M; Hey JA; Power A; Abushakra S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473975
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.
Uddin MS; Kabir MT; Rahman MS; Behl T; Jeandet P; Ashraf GM; Najda A; Bin-Jumah MN; El-Seedi HR; Abdel-Daim MM
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824102
[TBL] [Abstract][Full Text] [Related]
20. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
Suzuki N; Hatta T; Ito M; Kusakabe KI
Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
